CELG News 87.16 07/28/2014 04:50:53 Celgene Corp (CELG)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celgene Corp (CELG) 87.16 $CELG

Final Glance: Biotechnology companies
AP - Fri Jul 25, 5:12PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:

Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 2:45PM CDT
Celgene (CELG) reported higher than expected earnings on strong revenues.

Midday Glance: Biotechnology companies
AP - Fri Jul 25, 12:42PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:

Early Glance: Biotechnology companies
AP - Fri Jul 25, 9:21AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:

Why Celgene Stock Was Down 3% Today
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 24, 6:05PM CDT
Celgene  turned in a quarter that beat analyst expectations on the top and bottom lines, with revenue up 17% year-over-year and adjusted EPS up 18% year-over-year, yet the market didn't appear too impressed (the stock sold off about 3% today). In...

Shares of CELG Up 16.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jul 24, 4:50PM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 3 months, Celgene has returned 16.58% as of today's recent price of $86.19.

Celgene, Alexion Beat Estimates, But Biotechs Fall
at Investor's Business Daily - Thu Jul 24, 4:07PM CDT
Big-cap biotechs Celgene and Alexion Pharmaceuticals modestly beat Q2 estimates and raised their guidance early Thursday, but their shares tumbled as Wall Street seemed to turn against the sector. Celgene's (CELG) Q2 earnings rose 18% over the...

Celgene Stock Earnings: Key Takeaways
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 24, 4:03PM CDT
Celgene   is one of biotechnology's brightest shining stars. The company markets a slate of therapies, including its mega blockbuster multiple myeloma drug Revlimid, its fast-growing cancer drug Abraxane, and its newly launched autoimmune drug,...

Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 12:48PM CDT
The rise in healthcare spending, if true, will increase business for hospitals, diagnostic centers and healthcare related industry. Eventually, the healthcare industry should benefit and help healthcare funds be better investment potential.

Video: Celgene, Alexion Earnings Top, But Stocks Fall
at Investor's Business Daily - Thu Jul 24, 10:39AM CDT
Big-cap biotechs Celgene (CELG) and Alexion Pharmaceuticals (ALXN) both modestly beat Q2 estimates and raised their guidance Thursday morning, but their shares were falling in the stock market today as Wall Street seemed to hope for more. Celgene's...

Jim Cramer's Stop Trading: Consider Buying Celgene on Friday
at The Street - Thu Jul 24, 10:10AM CDT
TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, reasoned that investors should buy the weakness in Celgene.

Stocks Up And Down At Open; Under Armour, Facebook Surge
at Investor's Business Daily - Thu Jul 24, 9:31AM CDT
Stocks opened in a narrowly mixed stance Thursday. The Dow Jones industrial average and the S&P 500 inched up a fraction each. The Nasdaq dipped 0.1% as Qualcomm (QCOM), Celgene (CELG) and Alexion Pharmaceuticals (ALXN) dived after delivering...

Celgene's Narrow Beat on Second-Quarter Earnings Fails to Impress Investors; Shares Fall
George Budwell, The Motley Fool - Motley Fool - Thu Jul 24, 9:23AM CDT
Celgene Corporation reported second-quarter earnings  before the bell today, posting an adjusted diluted EPS of $0.90 on a split-adjusted basis, narrowly beating the Street's expectations by $0.01. The company generated $1.873 billion in revenue...

Stock Market News for July 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 9:10AM CDT
Benchmarks finished mostly higher on Wednesday following upbeat quarterly results from healthcare and technology companies

Celgene (CELG) Stock Falls After Mixed Second-Quarter Earnings
at The Street - Thu Jul 24, 8:16AM CDT
Celgene (CELG) dipped 2.21% to $87.15 in pre-market trading on Thursday after the biotechnology company reported mixed second-quarter results.

Today's Top Health Care Stocks: Alexion Pharmaceuticals, Bristol-Myers Squibb, Celgene Corp. and Eli
George Budwell, The Motley Fool - Motley Fool - Thu Jul 24, 7:46AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Alexion Pharmaceuticals , Bristol-Myers Squibb , Celgene Corporation and  Eli Lilly .  Alexion tops consensus for the second quarter Alexion beat...

Celgene Reports Second Quarter 2014 Operating and Financial Results
Business Wire - Thu Jul 24, 6:31AM CDT
--- Data on GED-0301, MDS-005 and MCL-002 to be Presented H2 2014

Jim Cramer's Top Stock Picks: PEP CELG GILD REGN BIIB CMG
at The Street - Thu Jul 24, 5:00AM CDT
Cramer says Chipotle is a huge winner while his 'four horsemen' of Celgine, Gilead Sciences, Regeneron and Biogen Idec are pulling away from the biotech pack.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Off-Broadway Play 'DUST' Raises Autism Support Funds

Updated Category News Views 401

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

Continue Reading
FuelCell Faces Class Action Crunch as Deadline Looms

Updated Category News Views 239

FuelCell's Legal Storm: What to Know Now You ever get that feeling when your gut knows it all before you even finish reading the headline? Well, buckle up, because FuelCell Energy, Inc. (NASDAQ:FCEL) is staring down a potential class-action train wreck, and they ain't got much track left to skid on before the deadline hits hard on November 10th, 2026. The Crunchy Details...

Continue Reading
Paris Baguette Pioneers Drive-Thru in Oklahoma

Updated Category News Views 659

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 157

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 508

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
ecozy's Brezzano Switch: Brewing Simplicity at Home

Updated Category News Views 499

Breathe the aroma, sip the innovation. ecozy just threw their Brezzano Switch into the arena, and here's the deal: it's a no-nonsense, get-your-caffeine-fix kind of machine aimed at making your mornings simple without compromising on flavor. Unique Features of the Brezzano Switch So, what's cooking? Get this—it's not just any coffee contraption. Built sleek and compact,...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 281

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 440

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 253

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 282

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading

Top 5 Most Recently Viewed Articles

Antengene's XPOVIO® Gains Approval in Thailand for Cancer Treatment

Updated Category News Views 114

Antengene's Recent Approval of XPOVIO® in Thailand Antengene Corporation Limited, a distinguished global biopharmaceutical company, has reached a notable achievement with the approval of XPOVIO® (selinexor) by the Thailand Food and Drug Administration. This approval marks XPOVIO® as the first and only XPO1 inhibitor authorized for sale in the Thai market. The drug,...

Continue Reading
Monumental Pediatric Surgery Advances at Nicklaus Children

Updated Category News Views 23

Redefining Pediatric Surgery with Mixed Reality Cue the drumroll, because Nicklaus Children's Hospital in Miami just pulled off a doozy in the medical field. The region's first pediatric total hip replacement using mixed reality-assisted guidance has taken place, and the ripples from this bad boy could be significant. The Hero of the Hour: Dr. Thomas J. Utset-Ward Dr....

Continue Reading
Contrasting Luxury Real Estate Trends in the U.S. Market

Updated Category News Views 151

The Evolving Landscape of U.S. Luxury Real Estate In the world of luxury real estate, change is the only constant. A recent report sheds light on how the U.S. luxury housing market is adapting to buyer preferences, with 2026 marking an interesting phase in pricing stabilization. Nationally, entry-level luxury prices stand steady at $1.19 million, but the interpretation of...

Continue Reading
Bureau Veritas Explores Potential Merger with SGS

Updated Category News Views 325

Exploring Business Synergies: Bureau Veritas and SGS Recent media discussions have shed light on the evolving landscape of Bureau Veritas as it engages in talks with SGS about the possibility of a business merger. This potential union reflects the growing trend within industries to enhance competencies and create greater value through collaboration. Bureau Veritas, a...

Continue Reading
Equifax Engages Investors in September Conferences Overview

Updated Category News Views 133

Equifax Invites Investors to Upcoming Conferences Equifax®, a leading data, analytics, and technology company recognized by its stock symbol EFX on the NYSE, is gearing up to engage with investors through several key conferences this September. This month presents an excellent opportunity for investors to gain insights into the company's strategy and future direction....

Continue Reading